Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial

Endothelial Progenitor cells (EPCs) has been shown to be dysfunctional in both type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) leading to poor regeneration of endothelium and renal perfusion. ...

Source: Cardiovascular Diabetology - June 3, 2020 Category: Cardiology Authors: Hassan B. Awal, Seshagiri Rao Nandula, Cleyton C. Domingues, Fiona J. Dore, Nabanita Kundu, Beda Brichacek, Mona Fakhri, Adrian Elzarki, Neeki Ahmadi, Shauna Safai, Magan Fosso, Richard L. Amdur and Sabyasachi Sen Tags: Original investigation Source Type: research